LONDON--GlaxoSmithKline PLC (GSK.LN), a research-based pharmaceutical and healthcare company said Tuesday that the European Commission has granted pazopanib marketing authorization for the treatment of patients with advanced soft tissue sarcoma or aSTS who have received prior chemotherapy or have progressed within 12 months after adjuvant therapy.
-Efficacy and safety has only been established in certain STS histological tumour subtypes.
-GlaxoSmithKline shares closed Tuesday at GBP15.06, valuing the company at GBP75.09 billion.
-Write to Razak Musah Baba at firstname.lastname@example.org
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
(END) Dow Jones Newswires
August 07, 2012 11:51 ET (15:51 GMT)
Copyright (c) 2012 Dow Jones & Company, Inc.